WO2006124630A3 - Compositions et procedes permettant d'augmenter l'efficacite de vaccins - Google Patents

Compositions et procedes permettant d'augmenter l'efficacite de vaccins Download PDF

Info

Publication number
WO2006124630A3
WO2006124630A3 PCT/US2006/018488 US2006018488W WO2006124630A3 WO 2006124630 A3 WO2006124630 A3 WO 2006124630A3 US 2006018488 W US2006018488 W US 2006018488W WO 2006124630 A3 WO2006124630 A3 WO 2006124630A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
vaccines
efficacy
enhancing
methods
Prior art date
Application number
PCT/US2006/018488
Other languages
English (en)
Other versions
WO2006124630A2 (fr
Inventor
Patricia Hibberd
Sherwood Gorbach
David Snydman
Barry Goldin
Original Assignee
New England Medical Center Inc
Univ Tufts
Patricia Hibberd
Sherwood Gorbach
David Snydman
Barry Goldin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Inc, Univ Tufts, Patricia Hibberd, Sherwood Gorbach, David Snydman, Barry Goldin filed Critical New England Medical Center Inc
Publication of WO2006124630A2 publication Critical patent/WO2006124630A2/fr
Publication of WO2006124630A3 publication Critical patent/WO2006124630A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à des compositions qui augmentent l'efficacité de vaccins, tels que les vaccins contre la grippe. L'invention concerne également des kits qui contiennent lesdites compositions, et des procédés d'utilisation des compositions et des kits pour traiter un sujet.
PCT/US2006/018488 2005-05-13 2006-05-12 Compositions et procedes permettant d'augmenter l'efficacite de vaccins WO2006124630A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68093505P 2005-05-13 2005-05-13
US60/680,935 2005-05-13

Publications (2)

Publication Number Publication Date
WO2006124630A2 WO2006124630A2 (fr) 2006-11-23
WO2006124630A3 true WO2006124630A3 (fr) 2007-01-04

Family

ID=37431928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018488 WO2006124630A2 (fr) 2005-05-13 2006-05-12 Compositions et procedes permettant d'augmenter l'efficacite de vaccins

Country Status (1)

Country Link
WO (1) WO2006124630A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2008106372A1 (fr) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Procédé de traitement ou de prévention d'une inflammation généralisée
US20110070334A1 (en) * 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
US20140093614A1 (en) * 2009-09-20 2014-04-03 Mead Johnson Nutrition Company Probiotic stabilization
FI20096058A0 (fi) * 2009-10-13 2009-10-13 Valio Oy Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
US20130195917A1 (en) * 2010-10-15 2013-08-01 Dorte Eskesen Immunoadjuvant
EP2455092A1 (fr) * 2010-11-11 2012-05-23 Nestec S.A. Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
CN103421715B (zh) * 2013-08-03 2015-06-10 青岛蔚蓝生物集团有限公司 一种鼠李糖乳杆菌及其应用
US10980269B2 (en) * 2016-12-12 2021-04-20 Mead Johnson Nutrition Company Protein hydrolysates and methods of making same
US20210393696A1 (en) * 2018-11-06 2021-12-23 Kansas State University Research Foundation Compositions for improving vaccine safety and efficacy and methods of use thereof
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
CA3198308A1 (fr) * 2020-11-10 2022-05-19 Dharanesh Mahimapura GANGAIAH Compositions probiotiques immunogenes et procedes d'utilisation, y compris a des fins de vaccination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUNOUT ET AL.: "Effects of a Nutritional Supplement on the Immune Response and Cytokine Production in Free-Living Chilean Elderly", JOURNAL PARENTERAL AND ENTERAL NUTRITION, vol. 28, no. 5, 2004, pages 348 - 354 *
YASUI ET AL.: "Reduction of Influenza Virus titer and Protection against Influenza Virus Infection in infant Mice Fed Lactobacillus casei Shirota", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 11, no. 4, July 2004 (2004-07-01), pages 675 - 679 *

Also Published As

Publication number Publication date
WO2006124630A2 (fr) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006124630A3 (fr) Compositions et procedes permettant d'augmenter l'efficacite de vaccins
WO2006119295A3 (fr) Compositions et methodes de traitement de maladies neurodegeneratives
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2007011962A3 (fr) Traitement du cancer
WO2006104945A3 (fr) Therapies contre l'hepatite c
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2011072099A3 (fr) Compositions et procédés comprenant des variants de protéase
WO2006069719A3 (fr) Lyophilisation de virosomes
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007015866A3 (fr) Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2008057550A3 (fr) Stabilisation de vaccins par lyophilisation
WO2008014008A3 (fr) Compositions et procédés pour moduler l'angiogenèse
WO2008013589A3 (fr) Traitement de tumeurs exprimant ras
WO2006091722A3 (fr) Vaccination amplifiee par alkyle-glycosides
WO2009133573A3 (fr) Formulation homéopathique
EP1885803A4 (fr) Compositions d'adjuvants agricoles, compositions herbicides, et leurs methodes d'utilisation
WO2007015877A3 (fr) Inhibiteurs de la p38 kinase et procedes permettant de traiter les troubles inflammatoires
WO2008121506A3 (fr) Inhibiteurs de la rénine
WO2008112192A3 (fr) Anticorps epha3 utilises dans le traitement des tumeurs solides
WO2009002440A3 (fr) Compositions comprenant un arnsi de egfr humain et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06770283

Country of ref document: EP

Kind code of ref document: A2